Neuropsychiatric Disorders (eBook) von Manfred Gerlach

The meeting of minds and times with Peter Riederer: an appreciation.- Succi nervorum: a brief history of neurochemistry.- Neuronal differentiation and long-term culture of the human neuroblastoma line SH-SY5Y.- Endogenous oxidized indoles share inhibitory potency against [3H]isatin binding in rat brain.- Lipid content determines aggregation of neuromelanin granules in vitro.- Hydrogen peroxide is a true first messenger.- The therapeutic potential of siRNA in gene therapy of neurodegenerative disorders.- Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis.- Luteolin protects rat PC 12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keapl-Nrf2-ARE pathway.- Behavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals.- Animal models in neurodegenerative diseases.- Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study.- Ginsenoside Rd attenuates neuroinflammation of dopaminergic cells in culture.- Biochemistry of postmortem brains in Parkinsons disease: historical overview and future prospects.- Neuroprotection by propargylamines in Parkinsons disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.- Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinsons disease.- Low dose methylphenidate improves freezing in advanced Parkinsons disease during off-state.- The long-term effects of the neurotoxin l-trichloromethyl-1,2,3,4-tetrahydro-?-carboline (TaClo) on cognitive performance in rats.- Observations on the cortical silent period in Parkinsons disease.- CYP 2E1 mutant mice are resistant toDDC-induced enhancement of MPTP toxicity.- Pharmacokinetic studies of ()-deprenyl and some of its metabolites in mouse.- Serum lipoprotein profile and APOE genotype in Alzheimers disease.- VITA study: white matter hyperintensities of vascular and degenerative origin in the elderly.- ?-Lipoic acid as a new treatment option for Alzheimers disease a 48 months follow-up analysis.- Long-term abnormalities in brain glucose/energy metabolism after inhibition of the neuronal insulin receptor: implication of tau-protein.- Long-term tetrahydroaminoacridine treatment and quantitative EEG in Alzheimers disease.- Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimers disease.- Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach.- Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimers disease and diabetes mellitus.- Improving linear modeling of cognitive decline in patients with mild cognitive impairment: comparison of two methods.- Interaction of attention and graphomotor functions in children with attention deficit hyperactivity disorder.- Therapeutic drug monitoring of antidepressants clinical aspects.- The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view.- Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia.- Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice.- FZD3 is not a risk gene for schizophrenia: a case-control study in a Caucasian sample.- Impaired cortical inhibition in adult ADHD patients: a study with transcranial magnetic stimulation*.- Association of Parkinsonsdisease with symptoms of attention deficit hyperactivity disorder in childhood.- Biostatistical analysis of gene microarrays reveals diverse expression clusters between macaque subspecies in brain SIV infection.- Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis.- Neural stem cell transplantation in a model of fetal alcohol effects.

This multidisciplinary book includes current research papers and reviews in the areas of basic neuroscience, neural mechanisms underlying neurodegenerative disorders. It further includes new approaches for neuroprotective treatments, clinical, neurobiological and treatment aspects of psychiatric disorders. The book was conceived as a celebration of the professional life and work of Peter Riederer to mark the occasion of his retirement.